Truist analyst Joon Lee lowered the firm’s price target on Viking Therapeutics (VKTX) to $75 from $95 but keeps a Buy rating on the shares. 2025 will be a year of execution as Viking embarks on Phase 3 program in obesity, though given intensifying competition in the obesity space, the firm is moderating its estimates, the analyst tells investors in a research note. Truist adds however that even a modest penetration into obesity, the largest therapeutic category, should be material for Viking.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VKTX:
- Viking Therapeutics participates in a conference call with Maxim Group
- Promising Developments and Strong Financial Position Bolster Buy Rating for Viking Therapeutics
- Viking Therapeutics: Promising Pipeline and Strategic Execution Drive Buy Rating
- Viking Therapeutics price target lowered to $85 from $96 at B. Riley
- Viking Therapeutics: Strong Financials and Promising VK2735 Program Drive Buy Rating